DexCom (DXCM) Stock Price, News & Analysis

Company Overview

DexCom, Inc. (NASDAQ: DXCM) is a San Diego–based medical technology company specializing in continuous glucose monitoring (CGM) systems for people living with diabetes. Founded in 1999, the company has led the industry in developing minimally invasive sensors and transmitters that provide real-time glucose readings, reducing reliance on fingerstick measurements and enabling more proactive glycemic management.

DexCom’s flagship offering, the G6 CGM system, launched in 2018 and features a small, wearable sensor, an ergonomic transmitter and a mobile application that delivers customizable alerts and trend data. In 2022, the company introduced the G7 system, which offers a shorter warm-up period, an all-in-one sensor-transmitter design and simplified insertion. Beyond patient-facing devices, DexCom markets professional CGM solutions for clinic-based applications and provides the Dexcom CLARITY software platform to aggregate sensor data and generate insights that support individualized therapy adjustments and remote patient monitoring.

The company distributes its CGM products globally through direct sales, specialty distributors and partnerships with insulin pump manufacturers and digital health platforms. DexCom systems are cleared or approved for use in major markets including the United States, Europe, Canada, Australia and Japan. Under the leadership of President and CEO Kevin Sayer, DexCom continues to pursue product innovation, strategic collaborations and expanded access initiatives aimed at delivering more accurate, user-friendly glucose monitoring to healthcare providers and patients around the world.

Key Stats

• Today's Range: $83.23 to $84.78
• 50-Day Range: $79.84 to $87.57
• 52-Week Range: $57.52 to $113.28
• Volume: 2.62 million shs
• Average Volume: 4.43 million shs
• Market Capitalization: $32.89 billion
• P/E Ratio: 62.60
• Dividend Yield: N/A
• Price Target: $99.60
• Consensus Rating: Moderate Buy

DexCom Stock Analysis - MarketRank™

DexCom scored higher than 96% of companies evaluated by MarketBeat, and ranked 53rd out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

DexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 16 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

DexCom has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 21.18%

Earnings Growth

Earnings for DexCom are expected to grow by 21.18% in the coming year, from $2.03 to $2.46 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of DexCom is 62.60, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.51.

Price to Earnings Ratio vs. Sector

The P/E ratio of DexCom is 62.60, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.06.

Price to Earnings Growth Ratio

DexCom has a PEG Ratio of 1.79. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

DexCom has a P/B Ratio of 15.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.69% of the float of DexCom has been sold short.

Short Interest Ratio / Days to Cover

DexCom has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in DexCom has recently increased by 12.05%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

DexCom does not currently pay a dividend.

Dividend Growth

DexCom does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.76

Percentage of Shares Shorted

2.69% of the float of DexCom has been sold short.

Short Interest Ratio / Days to Cover

DexCom has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in DexCom has recently increased by 12.05%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.36

News Sentiment

DexCom has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for DexCom this week, compared to 27 articles on an average week.

Search Interest

13 people have searched for DXCM on MarketBeat in the last 30 days. This is an increase of 44% compared to the previous 30 days.

MarketBeat Follows

7 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,281,732.00 in company stock.

Percentage Held by Insiders

Only 0.32% of the stock of DexCom is held by insiders.

Percentage Held by Institutions

97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DXCM Stock Analysis - Frequently Asked Questions

How have DXCM shares performed this year?

DexCom's stock was trading at $77.77 at the beginning of 2025. Since then, DXCM shares have increased by 7.9% and is now trading at $83.89.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) announced its quarterly earnings data on Thursday, May, 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by $0.01. The firm's revenue for the quarter was up 12.5% compared to the same quarter last year.
Read the conference call transcript.

When did DexCom's stock split?

DexCom shares split on Friday, June 10th 2022.The 4-1 split was announced on Friday, March 25th 2022. The newly issued shares were distributed to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

Does DexCom have any subsidiaries?

DexCom subsidiaries include these companies: TypeZero Technologies Inc, Nintamed Handels GmbH, DexCapital LLC, DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom (Canada) Inc., DexCom Deutschland GmbH, and others.

Who are DexCom's major shareholders?

DexCom's top institutional investors include Assenagon Asset Management S.A. (0.31%), Congress Asset Management Co. (0.27%), Chicago Capital LLC (0.23%) and Zevenbergen Capital Investments LLC (0.16%). Insiders that own company stock include Kevin R Sayer, Jacob Steven Leach, Jereme M Sylvain, Steven Robert Pacelli, Sadie Stern, Michael Jon Brown, Barry J Regan, Mark G Foletta, Steven R Altman, Paul R Flynn, Shelly Ramasamy Selvaraj, Matthew Vincent Dolan, Nicholas Augustinos and Bridgette P Heller.
View institutional ownership trends.

How do I buy shares of DexCom?

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some other companies that DexCom investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Invesco QQQ (QQQ).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:DXCM
• CIK: 1093557
• Web: www.dexcom.com
• Phone: (858) 200-0200
• Fax: 858-200-0201
• Employees: 10,300
• Year Founded: 1999

Price Target and Rating

• Average Price Target for DexCom: $99.60
• High Price Target: $120.00
• Low Price Target: $85.00
• Potential Upside/Downside: +18.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.91
• Research Coverage: 22 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.34
• Trailing P/E Ratio: 62.60
• Forward P/E Ratio: 41.33
• P/E Growth: 1.79
• Net Income: $576.20 million
• Net Margins: 12.90%
• Pretax Margin: 17.62%
• Return on Equity: 30.05%
• Return on Assets: 10.00%

Debt

• Debt-to-Equity Ratio: 0.55
• Current Ratio: 1.50
• Quick Ratio: 1.32

Sales & Book Value

• Annual Sales: $4.03 billion
• Price / Sales: 8.16
• Cash Flow: $2.24 per share
• Price / Cash Flow: 37.42
• Book Value: $5.38 per share
• Price / Book: 15.59

Miscellaneous

• Outstanding Shares: 392,110,000
• Free Float: 390,852,000
• Market Cap: $32.89 billion
• Optionable: Optionable
• Beta: 1.44